AI
VVOS icon

Aperture Investors’s Vivos Therapeutics VVOS Stock Holding History

Aperture Investors’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,411
Closed -$143K – 97
2021
Q3 		$143K Buy
1,411
+107
+8% +$11.2K 0.02% 81
2021
Q2 		$161K Buy
+1,304
New +$212K 0.02% 96

Other funds holding VVOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Aperture Investors's VVOS Position: Q4 2021 in Review

Aperture Investors sold out of Vivos Therapeutics (VVOS) in Q4 2021, closing a stake of 1,411 shares — an estimated $143K sold.

Aperture Investors first reported a position in VVOS in Q2 2021 and held it in 2 quarters. The position peaked at $161K in Q2 2021. 29 funds tracked by Wall St. Rank hold VVOS as of Q4 2021.

  • Aperture Investors reported no remaining Vivos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Aperture Investors sold 1,411 Vivos Therapeutics shares in Q4 2021, an estimated $143K.
  • Aperture Investors first reported a position in Vivos Therapeutics in Q2 2021 and held it in 2 quarters.
  • Aperture Investors's Vivos Therapeutics position peaked at $161K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2021.

Based on Aperture Investors's 13F filing for Q4 2021, filed 14 Feb 2022.